MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào)，我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)。

Rivaroxaban

CAS No. : 366789-02-8

MCE 國(guó)際站：Rivaroxaban

產(chǎn)品活性：Rivaroxaban 是一種高效，選擇性直接的凝血因子 Xa (FXa) 抑制劑，IC₅₀ 為 0.7 nM，K_i 為 0.4 nM。

研究領(lǐng)域：Metabolic Enzyme/Protease

作用靶點(diǎn)：Factor Xa

In Vitro: Rivaroxaban (BAY 59-7939) is an oral, direct Factor Xa (FXa) inhibitor in development for the prevention and treatment of arterial and venous thrombosis. Rivaroxaban competitively inhibits human FXa (K_i 0.4 nM) with >10 000-fold greater selectivity than for other serine proteases; it also inhibits prothrombinase activity (IC₅₀ 2.1 nM). Rivaroxaban inhibits endogenous FXa more potently in human and rabbit plasma (IC₅₀ 21 nM) than rat plasma (IC₅₀ 290 nM). It demonstrates anticoagulant effects in human plasma, doubling prothrombin time (PT) and activates partial thromboplastin time at 0.23 and 0.69 μM, respectively.

In Vivo: Rivaroxaban (BAY 59-7939) is a potent and selective, direct FXa inhibitor with excellent in vivo activity and good oral bioavailability. Rivaroxaban (BAY 59-7939), administered by i.v. bolus before thrombus induction, reduces thrombus formation (ED₅₀ 0.1 mg/kg), inhibits FXa, and prolongs PT dose dependently. PT and FXa are affected slightly at the ED₅₀ (1.8-fold increase and 32% inhibition, respectively). At 0.3 mg/kg (dose leading to almost complete inhibition of thrombus formation), Rivaroxaban moderately prolongs PT (3.2±0.5-fold) and inhibits FXa activity (65±3%).

相關(guān)產(chǎn)品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Metabolism/Protease Compound Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  Antiviral Compound Library  |  Drug Repurposing Compound Library  |  Anti-Cardiovascular Disease Compound Library  |  NMPA-Approved Drug Library  |  Orally Active Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Targeted Diversity Library  |  Rare Diseases Drug Library  |  EMA-Approved Drug Library  |  FDA-Approved Anticancer Drug Library  |  Coagulation and Anti-coagulation Compound Library  |  Off-patent Drug Library  |  Highly Selective Inhibitors Library  |  Edoxaban tosylate  |  Delparantag  |  BMS-262084  |  5-R-Rivaroxaban  |  Edoxaban-d₆  |  Methoxycarbonyl-D-Nle-Gly-Arg-pNA  |  FXIa-IN-9  |  Gabexate mesylate  |  Betrixaban hydrochloride  |  Abelacimab  |  RWJ-445167  |  Fondaparinux sodium  |  Heparin sodium salt (MW 15kDa)  |  ARC19499  |  BMS-654457  |  FXIa-IN-6  |  Boc-Ile-Glu-Gly-Arg-AMC  |  Osocimab  |  FXIa-IN-13  |  EMD 495235  |  Bismuth subgallate  |  Asundexian  |  FXIa-IN-1  |  LY-517717  |  Apixaban  |  Zifaxaban

熱門(mén)產(chǎn)品線：重組蛋白  |  化合物庫(kù)  |  天然產(chǎn)物  |  熒光染料  |  PROTAC  |  同位素標(biāo)記物  |  寡核苷酸  |  抗體  |  點(diǎn)擊化學(xué)

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry